Monopar Therapeutics IncNASDAQ:MNPRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6200
- TODAY'S CHANGE (%)-0.0370 (-5.6317%)
- Bid / Lots0.6200/ 63
- Ask / Lots0.6350/ 1
- Open / Previous Close0.6500 / 0.6570
- Day Range
- 52 Week Range
- Volume45,596
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MNPR |
|---|---|---|
| 09:32 ET | 2201 | 0.647 |
| 09:34 ET | 108 | 0.645 |
| 09:48 ET | 100 | 0.6401 |
| 09:50 ET | 100 | 0.645049 |
| 09:54 ET | 2042 | 0.6401 |
| 09:57 ET | 2611 | 0.64 |
| 10:01 ET | 100 | 0.64 |
| 10:06 ET | 7181 | 0.640037 |
| 10:30 ET | 100 | 0.64 |
| 10:48 ET | 100 | 0.626 |
| 11:04 ET | 798 | 0.632999 |
| 11:06 ET | 6187 | 0.626 |
| 11:08 ET | 4824 | 0.636845 |
| 11:27 ET | 200 | 0.630501 |
| 11:38 ET | 385 | 0.621 |
| 11:51 ET | 100 | 0.621 |
| 12:02 ET | 805 | 0.621 |
| 12:09 ET | 805 | 0.6397 |
| 12:21 ET | 1950 | 0.62 |
| 12:45 ET | 3906 | 0.63999 |
| 01:14 ET | 120 | 0.6202 |
| 01:24 ET | 100 | 0.62 |
| 01:28 ET | 906 | 0.6398 |
| 01:48 ET | 194 | 0.6398 |
| 02:33 ET | 5000 | 0.6398 |
| 02:38 ET | 3221 | 0.6397 |
| 03:07 ET | 100 | 0.6254 |
| 03:16 ET | 315 | 0.62 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Monopar Therapeutics Inc | 11.5M | -1.0x | --- |
Imunon Inc | 12.2M | -0.6x | --- |
Aslan Pharmaceuticals Ltd | 10.6M | -0.1x | --- |
National Graphite Corp | 10.5M | -3.1x | --- |
Enzolytics Inc | 12.8M | 0.0x | --- |
Cell MedX Corp | 12.8M | -11.0x | --- |
Company Information
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Contact Information
- Headquarters
- 1000 Skokie Blvd Ste 350WILMETTE, IL, United States 60091-1146
- Phone
- 847-388-0349
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Christopher Starr
- Chief Executive Officer, Director
- Chandler Robinson
- Chief Financial Officer, Treasurer, Company Secretary, Director
- Kim Tsuchimoto
- Chief Operating Officer
- Andrew Cittadine
- Acting Chief Medical Officer
- Patrice Rioux
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 17.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.18 |
EPS | $-0.61 |
Book Value | $0.37 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
